Since we focused on three target genes (RECK, MTSS1 and FOXF2) and investigated only 52 clinical samples, additional studies will be needed to elucidate the role of miR-182-5p in prostate cancer and its use in clinical applications. The gene discussed is FOXF2; the disease is prostate cancer.